News & Updates

Show Multimedia Only
Novel drug helps optimize HFrEF therapy

Novel drug helps optimize HFrEF therapy

27 Apr 2022 byAudrey Abella

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

Novel drug helps optimize HFrEF therapy

27 Apr 2022
Intensive urate lowering of little benefit to patients with erosive gout

Intensive urate lowering of little benefit to patients with erosive gout

27 Apr 2022